AEV
0.009
50%
KFM
0.061
-21.8%
VTA
0.021
31.3%
CMO
0.004
-20%
HIQ
0.005
25%
SRJ
0.004
-20%
VKA
0.011
22.2%
DTZ
0.026
-18.8%
WCN
0.023
21.1%
TZN
0.019
-17.4%
A8G
0.21
20%
FAU
0.01
-16.7%
MGU
0.006
20%
PL9
0.005
-16.7%
ABE
0.037
19.4%
UNT
0.005
-16.7%
JAV
0.097
18.3%
BRY
0.011
-15.4%
HMD
0.039
18.2%
CMP
0.235
-14.5%
SLA
0.13
18.2%
AGN
0.15
-14.3%
NYM
0.053
17.8%
GEN
0.006
-14.3%
EAU
0.14
16.7%
LRM
0.018
-14.3%
INF
0.007
16.7%
M4M
0.006
-14.3%
XST
0.014
16.7%
X2M
0.006
-14.3%
KLI
0.325
16.1%
SLB
0.275
-14.1%
HVY
0.4
15.9%
NOX
0.065
-13.3%
REC
0.037
15.6%
AS2
0.007
-12.5%
AHE
0.015
15.4%
AUV
0.007
-12.5%
DRX
0.016
14.3%
MRD
0.042
-12.5%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CMH Clinical trial openfor enrollment

Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759